Endocan elicits severe vascular inflammatory responses in vitro and in vivo

Journal of Cellular Physiology

Volumn 229, Issue 5, 2014, Pages 620-630

  Lee, Wonhwa ^a,b   Ku, Sae Kwang ^c   Kim, Shin Woo ^b   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ENDOCAN; LIPOPOLYSACCHARIDE; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTENSIVE CARE UNIT; LIGATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNCTURE; SEPSIS; SEVERE VASCULAR INFLAMMATORY RESPONSE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIBODIES; CECUM; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; PROTEOGLYCANS; SEPSIS;

EID: 84892637231     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24485     Document Type: Article

References (48)

1. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC. 2002. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 63:159-171.
2. Albelda SM, Smith CW, Ward PA. 1994. Adhesion molecules and inflammatory injury. FASEB J 8:504-512.
3. Anderson JM, Van Itallie CM. 1995. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol 269:G467-G475.
4. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. 1998. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47:1953-1959.
5. Bae JS. 2012. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Arch Pharm Res 35:1511-1523.
6. Bae JW, Bae JS. 2011. Barrier protective effects of lycopene in human endothelial cells. Inflamm Res 60:751-758.
7. Bae JS, Rezaie AR. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100:101-109.
8. Bae JS, Rezaie AR. 2009. Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost 101:513-520.
9. Bae JS, Rezaie AR. 2011. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118:3952-3959.
10. Bae JS, Yang L, Manithody C, Rezaie AR. 2007. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110:3909-3916.
11. Bae JS, Lee W, Rezaie AR. 2012. Polyphosphate elicits pro-inflammatory responses that are counteracted by activated protein C in both cellular and animal models. J Thromb Haemost 10:1145-1151.
12. Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, Pestel J, Dessaint JP, Tonnel AB, Lassalle P. 2001. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 167:3099-3106.
13. Bogatcheva NV, Verin AD. 2008. The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res 76:202-207.
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. 1992a. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
15. Bone RC, Sibbald WJ, Sprung CL. 1992b. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481-1483.
16. Brown RC, Davis TP. 2005. Hypoxia/aglycemia alters expression of occludin and actin in brain endothelial cells. Biochem Biophys Res Commun 327:1114-1123.
17. Buras JA, Holzmann B, Sitkovsky M. 2005. Animal models of sepsis: Setting the stage. Nat Rev Drug Discov 4:854-865.
18. Che W, Lerner-Marmarosh N, Huang Q, Osawa M, Ohta S, Yoshizumi M, Glassman M, Lee JD, Yan C, Berk BC, Abe J. 2002. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: Role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circ Res 90:1222-1230.
19. Csortos C, Kolosova I, Verin AD. 2007. Regulation of vascular endothelial cell barrier function and cytoskeleton structure by protein phosphatases of the PPP family. Am J Physiol Lung Cell Mol Physiol 293:L843-L854.
20. Essler M, Hermann K, Amano M, Kaibuchi K, Heesemann J, Weber PC, Aepfelbacher M. 1998. Pasteurella multocida toxin increases endothelial permeability via Rho kinase and myosin light chain phosphatase. J Immunol 161:5640-5646.
21. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. 2005. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280:17286-17293.
22. Friedman G, Silva E, Vincent JL. 1998. Has the mortality of septic shock changed with time. Crit Care Med 26:2078-2086.
23. Goeckeler ZM, Wysolmerski RB. 1995. Myosin light chain kinase-regulated endothelial cell contraction: The relationship between isometric tension, actin polymerization, and myosin phosphorylation. J Cell Biol 130:613-627.
24. Hanley JA, McNeil BJ. 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843.
25. Hansson GK, Libby P. 2006. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 6:508-519.
26. Hofbauer R, Moser D, Salfinger H, Frass M, Kapiotis S. 1998. Sufentanil inhibits migration of human leukocytes through human endothelial cell monolayers. Anesth Analg 87:1181-1185.
27. Huang GW, Tao YM, Ding X. 2009. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54:389-394.
28. Kim TH, Ku SK, Lee IC, Bae JS. 2012. Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Rep 45:200-205.
29. Kirkpatrick CJ, Wagner M, Hermanns I, Klein CL, Kohler H, Otto M, van Kooten TG, Bittinger F. 1997. Physiology and cell biology of the endothelium: A dynamic interface for cell communication. Int J Microcirc Clin Exp 17:231-240.
30. Komarova YA, Mehta D, Malik AB. 2007. Dual regulation of endothelial junctional permeability. Sci STKE 2007:re8.
31. Konari K, Sawada N, Zhong Y, Isomura H, Nakagawa T, Mori M. 1995. Development of the blood-retinal barrier in vitro: Formation of tight junctions as revealed by occludin and ZO-1 correlates with the barrier function of chick retinal pigment epithelial cells. Exp Eye Res 61:99-108.
32. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB. 1996. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271:20458-20464.
33. Lee JD, Huh JE, Jeon G, Yang HR, Woo HS, Choi DY, Park DS. 2009. Flavonol-rich RVHxR from Rhus verniciflua stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol 9:268-276.
34. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, Fisher CJ, Jr., Faist E, Reinhart K. 2003. Measures, markers, and mediators: Toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 31:1560-1567.
35. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE. 2005. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 280:25048-25059.
36. Mehta D, Malik AB. 2006. Signaling mechanisms regulating endothelial permeability. Physiol Rev 86:279-367.
37. Moy AB, Shasby SS, Scott BD, Shasby DM. 1993. The effect of histamine and cyclic adenosine monophosphate on myosin light chain phosphorylation in human umbilical vein endothelial cells. J Clin Invest 92:1198-1206.
38. Newton K, Dixit VM. 2012. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 4.
39. Panes J, Perry M, Granger DN. 1999. Leukocyte-endothelial cell adhesion: Avenues for therapeutic intervention. Br J Pharmacol 126:537-550.
40. Peters K, Unger RE, Brunner J, Kirkpatrick CJ. 2003. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 60:49-57.
41. Qiao RL, Wang HS, Yan W, Odekon LE, Del Vecchio PJ, Smith TJ, Malik AB. 1995. Extracellular matrix hyaluronan is a determinant of the endothelial barrier. Am J Physiol 269:C103-C109.
42. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stohr R, Hartmann A, Provenzano M, Otto VI, Detmar M. 2013. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73:1097-1106.
43. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. 2006. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25-37.
44. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664.
45. Walker RE, Spooner KM, Kelly G, McCloskey RV, Woody JN, Falloon J, Baseler M, Piscitelli SC, Davey RT, Jr., Polis MA, Kovacs JA, Masur H, Lane HC. 1996. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 174:63-68.
46. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Metz C, Miller EJ, Tracey KJ, Ulloa L. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216-1221.
47. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC. 2006. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203:1447-1458.
48. Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL. 2008. Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: We could go faster. J Crit Care 23:455-460.